Results 161 to 170 of about 53,193 (289)

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

PRKAR1A/RET Fusion Protein [PDF]

, 2020
openaire   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, Volume 20, Issue 3, Page 629-636, March 2026.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

The clinical significance of RET gene fusion among Chinese patients with lung cancer [PDF]

, 2020
Puyuan Xing, Nong Yang, Xue Hu, Yuxin Mu, Shouzheng Wang, Yiying Guo, Xuezhi Hao, Xingsheng Hu, Xinwei Zhang, Junling Li   +9 more
openalex   +1 more source

PCM1/RET Fusion Gene [PDF]

, 2020
openaire   +1 more source

Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma [PDF]

JCO Precision Oncology, 2021
Angela Mweempwa, Huiling Xu, Joseph H. A. Vissers, Richard W. Tothill, Andrew D. Pattison, Andrew P. Fellowes, David M. Thomas, Gary Richardson, Rodney J. Hicks, Sean M. Grimmond, Stephen B. Fox, Stephen J. Luen, Jayesh Desai, Benjamin J. Solomon   +13 more
openaire   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, Volume 20, Issue 3, Page 588-610, March 2026.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

P1.12B.09 Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials [PDF]

B. Solomon, A. Drilon, K. Park, Silvia Novello, E. Nadal, B. Besse, Nir Peled, Patrick Peterson, Scott Barker, Anna M. Szpurka, Olivera Grbovic-Huezo, Herbert H. Loong   +11 more
openalex   +1 more source

KIF5B/RET Fusion Gene [PDF]

, 2020
openaire   +1 more source

Preservation of cell‐free RNA in percutaneous core‐needle biopsy specimens' supernatants from non‐small cell lung cancer improves genomic testing performance

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract This prospective single‐center study aimed to investigate whether preserving cell‐free ribonucleic acid (cfRNA) in specimens' supernatants (SS) obtained from percutaneous core‐needle biopsy (CNB) of non‐small cell lung cancer (NSCLC) can improve the performance of genomic testing.
Sheng Xu, Yi‐Dan Ma, Zhi‐Xin Bie, Jing‐Yu Huang, Yuan‐Ming Li, Zheng Wang, Xiao‐Guang Li   +6 more
wiley   +1 more source